Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its blockbuster semaglutide (GLP-1 RA)-based therapies, Wegovy for obesity and ...

Once everyone’s had enough of injections, side effects, and the vast expense of GLP-1 drugs, it could be natural alternatives’ time to shine GLP-1 drugs first came onto the market to treat type 2 ...

Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Cigna offers a high yield, strong dividend growth, and robust earnings from healthcare segments.

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up ...

Concern over the cost of GLP-1 weight-loss drugs like Novo Nordisk's Wegovy has surged ... While some employers have covered GLP-1s, hoping for long-term health savings, rising prices are forcing a ...

Among employers with 500 or more workers, 51% said they planned to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers ...